Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia.
about
Mechanisms for the modulation of dopamine d(1) receptor signaling in striatal neuronsEvaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverinePhosphodiesterase Inhibition and Regulation of Dopaminergic Frontal and Striatal Functioning: Clinical ImplicationsIdentification and Optimization of PDE10A Inhibitors Using Fragment-Based Screening by Nanocalorimetry and X-ray CrystallographyPhosphodiesterases as therapeutic targets for Alzheimer's disease.Differential changes in amygdala and frontal cortex Pde10a expression during acute and protracted withdrawalTAK-063, a PDE10A Inhibitor with Balanced Activation of Direct and Indirect Pathways, Provides Potent Antipsychotic-Like Effects in Multiple ParadigmsInhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating.Phosphodiesterase 10A regulates alcohol and saccharin self-administration in ratsRadiosynthesis and in vivo evaluation of [11C]MP-10 as a PET probe for imaging PDE10A in rodent and non-human primate brainInhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical StimulationEffects of a novel phosphodiesterase 10A inhibitor in non-human primates: A therapeutic approach for schizophrenia with improved side effect profileSelective Effects of PDE10A Inhibitors on Striatopallidal Neurons Require Phosphatase Inhibition by DARPP-32(1,2,3)Comparison of [(11)C]TZ1964B and [(18)F]MNI659 for PET imaging brain PDE10A in nonhuman primatesPhosphodiesterase 10A Is Tethered to a Synaptic Signaling Complex in StriatumPhosphodiesterase regulation of alcohol drinking in rodents.Review: Modulation of striatal neuron activity by cyclic nucleotide signaling and phosphodiesterase inhibitionPDE10A inhibitors stimulate or suppress motor behavior dependent on the relative activation state of the direct and indirect striatal output pathwaysPhosphodiesterase 10A inhibitor MP-10 effects in primates: comparison with risperidone and mechanistic implicationsBiallelic Mutations in PDE10A Lead to Loss of Striatal PDE10A and a Hyperkinetic Movement Disorder with Onset in InfancyCyclic AMP control measured in two compartments in HEK293 cells: phosphodiesterase K(M) is more important than phosphodiesterase localizationGenome-wide association study in bipolar patients stratified by co-morbidityInhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's diseaseModulation of mGlu2 Receptors, but Not PDE10A Inhibition Normalizes Pharmacologically-Induced Deviance in Auditory Evoked Potentials and Oscillations in Conscious Rats.The prototypical ranitidine analog JWS-USC-75-IX improves information processing and cognitive function in animal modelsPhosphodiesterase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease-related phenotypes.Neurophysiological biomarkers for drug development in schizophrenia.Effect of chronic antipsychotic treatment on striatal phosphodiesterase 10A levels: a [¹¹C]MP-10 PET rodent imaging study with ex vivo confirmation.Nitric oxide-soluble guanylyl cyclase signaling regulates corticostriatal transmission and short-term synaptic plasticity of striatal projection neurons recorded in vivoPhosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair.Bioactivities of Compounds from Elephantopus scaber, an Ethnomedicinal Plant from Southwest China.cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.Inhibition of phosphodiesterase10A attenuates morphine-induced conditioned place preference.Schizophrenia drug discovery and development in an evolving era: are new drug targets fulfilling expectations?Discovery of novel PDE10 inhibitors by a robust homogeneous screening assay.Alzheimer's disease and age-related memory decline (preclinical)Synthesis and in vitro characterization of cinnoline and benzimidazole analogues as phosphodiesterase 10A inhibitors.Synthesis and in vitro evaluation of new analogues as inhibitors for phosphodiesterase 10A.Facilitation of corticostriatal transmission following pharmacological inhibition of striatal phosphodiesterase 10A: role of nitric oxide-soluble guanylyl cyclase-cGMP signaling pathways.Characterization of binding and inhibitory properties of TAK-063, a novel phosphodiesterase 10A inhibitor
P2860
Q21131062-10A3EB97-FC16-42A3-BBE0-2167506477A5Q24649503-3A88D575-1F12-4DAE-92AB-0B1CEBA50320Q26753116-E39C7B73-A4E3-4996-ACF2-CAFD6E114A10Q27681131-C7B7359A-0E2C-4B09-9CD9-704EE05E8DB6Q28279704-E8658A93-A6DF-4AAF-B307-D0D420609F57Q28383988-7EEAA98E-A4AD-43B6-9491-0949FE685EF0Q28384192-92E89B49-6766-4167-A811-F524891FE177Q28385659-8859E8AC-F340-40DE-B38B-D94B65B77D22Q28386042-4369F25F-D4D6-4ECC-AE4A-D3365B51C11FQ28386823-EA8CB493-99FF-4591-B7AA-6FF9BBB52A7BQ28387521-C1C110A1-4E36-40E5-981F-3B0C7ED22A68Q28389666-4604B598-E55F-49D6-999D-3D8DC55D41C6Q28390499-85C3EA5E-184F-4069-BCC2-8C32D55EC3C8Q28390557-35120D31-ACEB-4AB3-AAE8-4E2FF5488B83Q28393596-C9F9DED2-DF5D-409D-9214-F068FEE363DFQ28394978-F11294C2-AF88-43CD-9064-DEE17CB03FD6Q28394979-6D4B55E6-8C38-4D7B-AA15-102A1A47306AQ28395353-621B6B68-B213-47C5-A06C-6D588DD6E4FFQ28396609-E3FBB478-B21D-497F-B9DD-B5B6F1BF4429Q28592922-58620351-B64A-4140-8F6D-684C20243E92Q28740548-A03855E1-DC4A-43F5-ADDD-3D77B62A8794Q28741033-8552F91A-5ED1-4E4D-B4DA-3D95E26036B6Q28748849-31FF5B85-4804-41EE-880B-A12F29208C1FQ30391868-5CE433C4-531E-4DEB-9C23-86168940F479Q30470041-00CD7EE8-82B9-4643-A98B-C039634D7D97Q30478804-F19CBB20-24D7-4D52-B181-1B461C566C70Q30486447-C9BD820B-2475-400A-8B99-B33999A3D4C3Q33575007-24F82028-EE69-44C6-847B-5DAB55A8BAB4Q33618380-30B6BCE9-EFF5-403D-B950-9D7AF807329BQ33624262-9CE74796-DB8E-4D51-9112-03EBB715D98FQ33748655-5B173C0E-F7D7-41AA-A3DB-AE56D907CB6AQ34244951-704F2198-4AA6-4D3C-B70D-F6A851E94735Q34268331-2FD46AC3-5DAE-4763-B030-4497643BAC3FQ34458090-CB70B4CF-E2A3-4B3D-8BD8-65039DBA3E75Q34679687-244E6E31-4772-4193-B40A-8511636A0FDCQ35041190-305FDE45-72E2-42BF-8B0A-2BE831498090Q35063956-AE7AEBCF-C2BC-48CF-94D9-438A9C2D175CQ35190040-DD17C0BE-8EA9-493E-9BEB-217B4877D750Q35307838-82F2B38E-E745-4E71-A79C-7AE2CD4CE84CQ35588358-2AC57AD2-2349-4A93-8789-18DBFD8B8DE5
P2860
Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia.
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Preclinical characterization o ...... he treatment of schizophrenia.
@ast
Preclinical characterization o ...... he treatment of schizophrenia.
@en
Preclinical characterization o ...... he treatment of schizophrenia.
@nl
type
label
Preclinical characterization o ...... he treatment of schizophrenia.
@ast
Preclinical characterization o ...... he treatment of schizophrenia.
@en
Preclinical characterization o ...... he treatment of schizophrenia.
@nl
prefLabel
Preclinical characterization o ...... he treatment of schizophrenia.
@ast
Preclinical characterization o ...... he treatment of schizophrenia.
@en
Preclinical characterization o ...... he treatment of schizophrenia.
@nl
P2093
P356
P1476
Preclinical characterization o ...... he treatment of schizophrenia.
@en
P2093
A D Ramirez
C J Schmidt
C Proulx-LaFrance
D S Chapin
F D Tingley
F R Nelson
F S Menniti
J A Siuciak
J Cianfrogna
P304
P356
10.1124/JPET.107.132910
P407
P577
2008-02-20T00:00:00Z